Sobi and Hellenic Institute Report Results of Anakinra in P-III SAVE-MORE Study for Hospitalized Patients with COVID-19 Pneumonia

 Sobi and Hellenic Institute Report Results of Anakinra in P-III SAVE-MORE Study for Hospitalized Patients with COVID-19 Pneumonia

Sobi and Hellenic Institute Report Results of Anakinra in P-III SAVE-MORE Study for Hospitalized Patients with COVID-19 Pneumonia

Shots:

  • The P-III SAVE-MORE study involves assessing the efficacy and safety of anakinra (100mg/day, SC for up to 10 days) + SoC guided by suPAR vs PB0 + SOC in 600 hospitalized patients in mod. to sev. COVID-19 pneumonia over 28days across 40 sites in Greece and Italy
  • The study demonstrated improvement in the overall clinical outcomes by 64% @28 days as measured by the ordinal scale of the 11-point CPS, reduction in either death or progression to severe respiratory failure and increase the no. of patients who were discharged from hospital with no evidence of COVID-19 infection
  • Sobi plans to discuss the results with regulatory authorities to evaluate the possibility of approval

Click here to­ read full press release/ article | Ref: Sobi | Image: Sobi

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post